Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback